original ) (raw )Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Adam Savitz
Neuropsychiatric Disease and Treatment, 2019
View PDFchevron_right
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review
Miquel Bioque , Alexandre G González-Rodríguez , Rafael Penadés
Patient preference and adherence, 2015
View PDFchevron_right
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
Panna Sanga
International Journal of Neuropsychopharmacology, 2021
View PDFchevron_right
Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
Nagesh Pai
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2018
View PDFchevron_right
Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia
Andreas Conca
Expert Opinion on Pharmacotherapy, 2016
View PDFchevron_right
The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): A cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia
G. Steegen
2020
View PDFchevron_right
Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
Amber Edinoff
Frontiers in Psychiatry, 2021
View PDFchevron_right
Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
Clemente Garcia-rizo , Rafael Penadés , Alexandre G González-Rodríguez
Patient Preference and Adherence, 2015
View PDFchevron_right
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia
Lian Mao
CNS spectrums, 2016
View PDFchevron_right
A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
Pilar Lim
Neuropsychopharmacology, 2010
View PDFchevron_right
Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
Rosaria Di Lorenzo
Neuropsychiatric Disease and Treatment
View PDFchevron_right
Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
Peter Weiden
Patient Preference and Adherence, 2012
View PDFchevron_right
Effectiveness and Predictors of Continuation of Paliperidone Palmitate Long-Acting Injection Treatment
Marco Pereira
Journal of Clinical Psychopharmacology, 2015
View PDFchevron_right
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia
Mahesh Samtani , C. Gassmann-mayer
Current Medical Research and Opinion, 2010
View PDFchevron_right
A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia
Lian Mao
Schizophrenia Research, 2016
View PDFchevron_right
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
Cherubin, Pierre [JACFR] , Andreas Schreiner
Schizophrenia Research, 2015
View PDFchevron_right
Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
Boran Uglešić
Neuropsychiatric Disease and Treatment
View PDFchevron_right
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study
Adam Savitz
The Journal of Clinical Pharmacology, 2015
View PDFchevron_right
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
Adam Savitz
The International Journal of Neuropsychopharmacology, 2016
View PDFchevron_right
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
Pilar Lim
Schizophrenia Research, 2010
View PDFchevron_right
Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia
Lian Mao
The Journal of Clinical Psychiatry, 2015
View PDFchevron_right
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
Pilar Lim
Journal of Psychopharmacology, 2011
View PDFchevron_right
Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration
Euitae Kim
The Journal of Clinical Psychiatry, 2021
View PDFchevron_right
Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
Anthony Harris
Neuropsychiatric disease and treatment, 2015
View PDFchevron_right
One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients', Relatives', and Mental Health Professionals' Perspectives
Rikus Knegtering
Patient Preference and Adherence, 2022
View PDFchevron_right
A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents
Ludger Hargarter , Andreas Schreiner , Yasin Bez
Clinical therapeutics, 2014
View PDFchevron_right
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study
Robert Litman
The International Journal of Neuropsychopharmacology, 2009
View PDFchevron_right
Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
Mario Louzã
Neuropsychiatric Disease and Treatment
View PDFchevron_right